MS BioNTech WKN: A2PSR2 ISIN: US09075V1026 Kürzel: BNTX Forum: Aktien User: Thekla

WHO Omicron-Update von @mvankerkhove : 99,9 % der in den letzten 30 Tagen bereitgestellten Sequenzen waren #Omicron . „Von diesen sind etwa 75 % BA.2 und 25 % BA.1 … all dies sind besorgniserregende Varianten.“ Die Fähigkeit von @WHO zur Verfolgung des Virus wird jedoch beeinträchtigt, da die Testraten weltweit sinken. https://twitter.com/ghs/status/1504549632587677699?s=21

Auch bei Law Radar - es stimmt Pfizer was slapped with a patent infringement lawsuit Thursday in Delaware District Court over the delivery mechanism of its mRNA COVID-19 vaccine. The suit, filed by McDermott Will & Emery on behalf of Alnylam Pharmaceuticals Inc., asserts a single patent related to the use of lipid nanoparticles to deliver RNA to cells. Alnylam, a Cambridge, Massachusetts-based biotech company, also sued Pfizer on Thursday. The suits seek monetary damages and do not ask for injunctions. Counsel have not yet appeared for Pfizer. The case is 1:22-cv-00336, Alnylam Pharmaceuticals, Inc. v. Pfizer Inc., et al. https://www.law.com/radar/card/alnylam-pharmaceuticals-inc-v-pfizer-inc-et-al-43903951-0/

Thekla viele Treffer bei Google

Chillen wir weiter

https://www.businesstimes.com.sg/consumer/pfizer-moderna-sued-by-alnylam-in-new-fight-over-covid-shots?amp https://pharmaphorum.com/news/alnylam-sues-pfizer-moderna-over-covid-19-vaccines/ https://mobile.reuters.com/article/amp/idUSKCN2LE1AM https://www.finanznachrichten.de/nachrichten-2022-03/55529650-alnylam-files-patent-infringement-suits-against-pfizer-and-moderna-on-covid-19-vaccines-020.htm

Burgi 21.01 zu der Meldung habe nur auf Facebook und Twitter etwas gefunden

Das gibt gerade einen richtigen Dämpfer

Nach dem letzten Anstieg von gestern eine solide Basis für morgen.

165 Dollar meine ich Burgi

Richtig!

🇦🇹 #Inflation kletterte im Februar mit 5,9% auf höchsten Wert seit 1984

165 Dollar Punkt genau,und kein minus

Alnylam Pharmaceuticals said it had filed lawsuits against Pfizer and Moderna, alleging that the companies had infringed its patents for their Covid-19 vaccines. The biotechnology company claimed that lipid nanoparticle technology it developed was an important component of the vaccines, which have been given to millions of Americans and generated billions in revenue for Pfizer and Moderna. Alnylam said it is seeking damages. "The patent relates to Alnylam's biodegradable cationic lipids that are foundational to the success of the mRNA Covid-19 vaccines," Cambridge, Massachusetts-based Alnylam said in a release on Thursday (Mar 17). Alnylam uses lipid nanoparticles to deliver treatments into the body that silence malfunctioning genes, and numerous biotech companies are using them as a tool to advance genetic medicine. Pfizer and Moderna use lipid nanoparticles to protect the fragile messenger RNA that makes their Covid shots work. Alnylam said it won't seek an injunction or try to impede the production, sale or distribution of the vaccines. While the shots have been deployed worldwide, many people remain unvaccinated, and governments are still campaigning to expand immunisation and halt future waves of infection. Legal battles among drugmakers over intellectual property aren't unusual, and the Covid vaccines have stirred other disputes. The US government has claimed it holds key patents related to the Moderna shot. Additionally, Moderna is facing a separate patent lawsuit in Delaware over its Covid-19 vaccine from Arbutus Biopharma and Genevant Sciences. Moderna said in a statement that Alnylam's suit was "blatant opportunism" and that its nanoparticles "do not resemble Alnylam's work." The company said it designed proprietary lipids after discovering years ago that the Alnylam-style lipids didn't work for delivering mRNA directly into the arm. "Any assertion that the Alnylam patent covers Moderna's Covid-19 vaccine is specious," the company said. Pfizer, which has invested to scale up production of its lipid nanoparticles and clinched deals with partners to bolster supply, didn't immediately respond to a request for comment. Shares of Alnylam advanced 2.1 per cent at 10.25 am in New York on Thursday, while Pfizer gained 1.7 per cent and Moderna declined 3.1 per cent. "It is our fiduciary duty to shareholders to seek fair compensation for the use of our technology," Alnylam spokeswoman Christine Lindenboom said in a statement. BLOOMBERG

Gegenüber gestern + 0,30€

🍀🔔1️⃣4️⃣8️⃣7️⃣0️⃣🔔☘